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Abstract
The immunity of a host population against specific influenza A strains can influence a
number of important biological processes, from the emergence of new virus strains to the
effectiveness of vaccination programmes. However, the development of an individual’s
long-lived antibody response to influenza A over the course of a lifetime remains poorly un-
derstood. Accurately describing this immunological process requires a fundamental under-
standing of how the mechanisms of boosting and cross-reactivity respond to repeated
infections. Establishing the contribution of such mechanisms to antibody titres remains chal-
lenging because the aggregate effect of immune responses over a lifetime are rarely ob-
served directly. To uncover the aggregate effect of multiple influenza infections, we
developed a mechanistic model capturing both past infections and subsequent antibody re-
sponses. We estimated parameters of the model using cross-sectional antibody titres to
nine different strains spanning 40 years of circulation of influenza A(H3N2) in southern
China. We found that “antigenic seniority” and quickly decaying cross-reactivity were impor-
tant components of the immune response, suggesting that the order in which individuals
were infected with influenza strains shaped observed neutralisation titres to a particular
virus. We also obtained estimates of the frequency and age distribution of influenza infec-
tion, which indicate that although infections became less frequent as individuals progressed
through childhood and young adulthood, they occurred at similar rates for individuals above
age 30 y. By establishing what are likely to be important mechanisms driving epochal trends
in population immunity, we also identified key directions for future studies. In particular, our
results highlight the need for longitudinal samples that are tested against multiple historical
strains. This could lead to a better understanding of how, over the course of a lifetime, fast,
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transient antibody dynamics combine with the longer-term immune responses considered
here.
Author Summary
Host immunity against seasonal influenza viruses influences the emergence of new virus
strains, the size and severity of “flu” epidemics, and the effectiveness of vaccination pro-
grammes. However, the specific factors that shape the immune response of a single human
to a particular strain are little understood because individual infections and the develop-
ment of immunity over a lifetime in that person are rarely observed directly. To determine
the aggregate effect of a lifetime of influenza infections on host immunity, we developed a
mathematical model that captures the specific strains with which an individual has been
infected and for the corresponding antibody response, the relative contribution of boost-
ing, cross-reactivity, and antigenic seniority to its neutralising ability. Combining the
model with data from a survey in southern China that examined antibody levels against
nine different influenza strains from 1968 to 2009, we revealed key components of the im-
mune response to influenza virus infection, and obtained estimates of the frequency of in-
fluenza infection and the ages at which infection occurred. Our results suggest that
“antigenic seniority”, whereby strains encountered earlier in life gain more “senior” posi-
tions in the immune response, and short-lived cross-reactivity between different strains
are important components of the immune response and, therefore, could shape the evolu-
tion and emergence of influenza viruses.
Introduction
The immunity of a host population against specific influenza A strains can influence a number
of important biological processes. It can affect the emergence of new virus strains, and hence
shape the evolution of the disease [1,2]. It can also influence the size and severity of a pandemic
[3–6], and the effectiveness of vaccination programmes [7].
There are two main ways to measure the adaptive immune response against influenza virus-
es [8]. In microneutralisation assays, a mixture of virus and diluted serum is used to infect cell
cultures; the titre is the highest dilution for which virus infection is blocked. Microneutralisa-
tion titres therefore measure the overall neutralising antibody response. Such a response can
include several components. Some antibodies are specific to antigenic sites on the globular
head of the haemagglutinin (HA) surface protein. These sites are highly variable: the HA un-
dergoes frequent mutation, enabling the virus to escape existing antibody responses [9]. There
is also evidence that antibodies target conserved epitopes on the stalk of the HA protein or the
neuraminidase (NA) surface protein [10–12]. Alternatively, haemagglutination inhibition
(HAI) assays measure the extent to which antibodies inhibit binding of the HA protein to red
blood cells. Whereas microneutralisation titres likely capture more of the total antibody re-
sponse, the HAI assay is a more sensitive measure of antibodies that are specific for antigenic
sites on the head of the HA protein [13].
The ability of human sera to neutralise current and historical influenza strains exhibits sub-
stantial variation between individuals and with age [10,13–15]. These patterns are likely to be
influenced by a number of factors. First, neutralisation titres to a particular strain depend on
the immune response following exposure to that virus: after infection or vaccination, the
Estimating the Life Course of Influenza A(H3N2) Antibody Responses
PLOS Biology | DOI:10.1371/journal.pbio.1002082 March 3, 2015 2 / 16
Research (UK, for Health Protection Research Unit
funding). JL's work was supported by a grant from
NIAID (K22 AI092150-01). The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: HA, haemagglutinin; HAI,
haemagglutination inhibition; NA, neuraminidase.
immune response to a particular virus can be boosted [5]. Although the initial response may
decay to a lower level after a short period of time [16,17], there is evidence that the subsequent
level of response can persist for several decades [18].
Observed titres can also depend on the order and number of influenza infections. Francis
[14] coined the term “original antigenic sin” to describe the phenomenon by which HAI titres
to the first influenza infection of a lifetime were apparently higher than titres to other strains.
Upon subsequent infection, it has been suggested that the original response can be enhanced
[14,19–21] and the antibody response to the new strain reduced [22–26]; for original antigenic
sin to occur, there is evidence that the original and new strain must be antigenically related
[26,27]. Recent work has refined the original antigenic sin hypothesis, proposing that serologi-
cal patterns should be described in terms of “antigenic seniority” [13,15]. As with original
antigenic sin, the primary infection gains the most “senior” position in the immune response,
but—as a key refinement to the original sin hypothesis—the hierarchy of responses continues
with each subsequent infection, as each strain takes a less senior position in the response.
As well as boosting and original antigenic sin/antigenic seniority, observed serological re-
sponses can also depend on cross-reactivity between strains and temporal waning of responses.
Even if hosts have not been exposed to a given strain, they can have a raised titre against the
virus if the test strain is similar to those already encountered [5,18]. Establishing the contribu-
tion of different mechanisms to neutralisation titres remains challenging, however, because the
aggregate effect of immune responses over a lifetime are rarely observed directly [13,24]. More-
over, observed titres not only depend on the relationship between infection and immune re-
sponse: they are also influenced by the specific strains a host has been infected with. It has been
suggested that certain age groups are infected more often than others [28,29], but the true fre-
quency of influenza infection cannot be easily measured [30].
To explore the effects of past infections and subsequent immune responses on observed
microneutralisation titres, we fitted a mechanistic model of within-host serological dynamics
to data from a cross-sectional survey based in southern China [31]. In the study, 151 individu-
als’ sera were tested against a panel of nine different influenza A(H3N2) strains isolated be-
tween 1968 and 2008. Six of these strains corresponded to representative viruses from every
second “antigenic cluster” that appeared between 1968 and 2003; in total there were 11 such
clusters of antigenically similar strains during this period [32]. The other three test viruses
were strains that circulated in southern China between 2003 and 2008.
We used the mechanistic model to assess the relative contribution of boosting, cross-reactiv-
ity, and antigenic seniority to observed neutralisation titres, and estimated key immunological
parameters. We also estimated which specific strains each individual had been infected with,
and hence assembled infection histories for each individual in the study population. This made
it possible to calculate the frequency of infection for influenza A(H3N2) in the host population,
and to establish how the infection rate varied with age.
Materials and Methods
Ethics Statement
Study protocols and instruments were approved by the following institutional review boards:
Johns Hopkins Bloomberg School of Public Health, University of Liverpool, University of
Hong Kong, Guangzhou No. 12 Hospital, and Shantou University. Written informed consent
was obtained from all participants over 12 y of age, and verbal assent was obtained from partic-
ipants 12 y of age or younger. Written permission of a legally authorised representative was ob-
tained for all participants under the age of 18 y.
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Data
Participants were recruited from five study locations, with 20 households randomly selected in
each location (further details given in Lessler et al. [31]). Participants’ sera were tested against
nine representative influenza A(H3N2) strains using a virus neutralisation assay. The strains
included six vaccine strains: A/Hong Kong/1/1968, A/Victoria/3/1975, A/Bangkok/1/1979, A/
Beijing/353/1989, A/Wuhan/359/1995, and A/Fujian/411/2002. Three strains that circulated in
southern China in the years preceding the study were also tested: A/Shantou/90/2003, A/Shan-
tou/806/2005, and A/Shantou/904/2008. Titres were measured using serial 2-fold dilutions
from 1:10 to 1:1,280 in duplicate. In our analysis, we represented the results in terms of log neu-
tralisation titres. A log titre of c corresponded to a dilution of 10 × 2(c−1). Hence, there were
nine possible log titres: the lowest was 0, which corresponded to a dilution<1:10; the highest
was 8, which corresponded to a dilution of 1:1,280.
Model of Serological Dynamics
We took an “epochal” view of infection [32,33], with individuals either infected or not during
each antigenic epoch; we assumed there were 14 such epochs between 1968 and 2008. We mod-
elled serological titres by assuming that the mean neutralisation titre to a specific strain de-
pended on both individual infection history and a combination of serological mechanisms. We
considered four specific mechanisms: boosting from infection with the test strain, cross-reac-
tivity from antigenically similar strains, boosting of earlier responses as a result of subsequent
infection, and suppression of subsequent responses as a result of prior immunity. The final two
mechanisms have been suggested as potential explanations for observed patterns of antigenic
seniority [13,15].
We included the four main mechanisms in the model as follows. Suppose an individual has
an infection history that consists of a set of strains X (note that we do not distinguish between
live infection and vaccination in the model). We assumed that if an individual had been in-
fected with only one strain, they would exhibit a fixed log titre against that strain, controlled by
a single parameter, μ. In the absence of antigenic seniority or cross-reactivity, the individual
would therefore have titre equal to μ for every strain in their infection history, and zero for all
other strains (Fig. 1A). However, if the individual had been infected with more than one strain,
titres against earlier strains could be higher than those against later strains as a result of anti-
genic seniority.
Two mechanisms have been proposed to explain observed patterns of antigenic seniority:
previous responses might be boosted as a result of subsequent infections, or subsequent re-
sponses might be reduced as a result of previous immunity [15]. To evaluate the contribution
of these two mechanisms, we specified the model so that—depending on parameter values—
both, one, or neither mechanism could contribute to measured titres. During the fitting pro-
cess, model outputs could therefore be compared to observed serological data to establish
which mechanism(s) were most plausible given the data.
First, we assumed each infection could boost titres against strains encountered previously
by a parameter τ1 (Fig. 1B). Hence the titre μ was scaled by a factor s1(X, j) = (1 + τ1)
|X| − Nj
where Nj is the number of the strain in the infection history (i.e., the first strain is 1, the second
is 2, etc.) and |X| is the total number of infections. If τ1 = 0, then there was no boosting as a re-
sult of subsequent infection. This mechanism, in which observed titres to a particular strain de-
pended on the number of subsequent infections, was also proposed by Miller et al. [13]
following a longitudinal study of influenza A infections.
Second, we assumed prior immunity could reduce observed titres against strains encoun-
tered later in life (Fig. 1C). The titre against a particular strain would therefore be scaled by a
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factor s2ðX; jÞ ¼ et2ðNj1Þ. Here, observed titres to each strain depended on how many infec-
tions had occurred previously. When τ2 = 0, prior infections did not lead to reduced responses
against later strains. When τ2 was large, the formulation was equivalent to a model of original
antigenic sin, in which immunity from the primary infection suppressed all subsequent re-
sponses [28,34].
Finally, we incorporated cross-reactivity by assuming that mean titre against a specific strain
was equal to the sum of cross-reactive responses to all strains in an individual’s infection history.
We assumed that the contribution made by each strain depended on the temporal distance be-
tween the strain in the infection history and the test strain (Fig. 1D). The level of cross-reaction
between a test strain j and infecting strainm was given by d(j,m) = e−σ|tm − tj|, where |tm − tj| was
the number of years between strains j andm, and σ was a parameter to be fitted. If σ was large, it
was equivalent to having no cross-reactivity between strains.
To combine the four mechanisms in the model, we assumed that the log titre individual i
has against a strain j was Poisson distributed with the following mean:
lij ¼ m
X
m2X
dðj;mÞs1ðX;mÞs2ðX;mÞ ð1Þ
Fig 1. Schematic of mechanisms that shape observed titres in the model. (A) Simple boosting. In the absence of cross-reactivity and antigenic seniority,
if an individual had been infected with a particular strain, they exhibited a fixed response to that strain equal to μ. This was controlled by a single parameter in
the model. In the figure, strains are sorted by date of isolation, with serological samples taken in present day. Strains the host has been infected with are
shown in red; coloured bars show the magnitude of observed log titre as a result of past infection with each strain. (B) Boosting of prior responses via
antigenic seniority. Infections boosted observed titres to earlier infecting strains by a certain scaling factor, controlled by the parameter τ1. The magnitude of
titre to a particular strain therefore depends on the number of infections that occurred after infection with that strain. (C) Suppression of new responses via
antigenic seniority. The response to each strain was reduced as a result of immunity generated by previous infections. This reduction was controlled by the
parameter τ2. The titre to a particular strain therefore depended on the number of infections that occurred before that strain circulated. (D) Cross-reactivity. In
the absence of antigenic seniority, the observed titre to a test strain depended on the response as a result of infection with that strain, plus cross-reactive
responses from infection with other strains. These cross-reactive responses decreased with the distance (measured in years) between each infection and the
test strain. Strains that circulated further from the test strain in time contributed less to the observed response.
doi:10.1371/journal.pbio.1002082.g001
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As d(j,m), s1(X,m), or s2(X,m) could equal 1 for certain parameter values, the model was capa-
ble of omitting certain mechanisms if necessary.
We also accounted for potential observation error by assuming that there was a uniform
probability of observing a titre different to the true one. Hence, the likelihood of observing titre
cj against test strain j was equal to the sum over all possible true titres:
LðcjÞ ¼ m
X
k
Pðtrue titre is kÞ  Pðobserve cj j true titre is kÞ ð2Þ
We estimated model parameters using Markov chain Monte Carlo (details in S1 Text; dataset
and model outputs in S1 Data).
As a sensitivity analysis, we also included the waning of antibody responses in our model.
This was achieved by modifying Equation 1:
lij ¼ m
X
m2X
dð j;mÞs1ðX;mÞs2ðX;mÞe−wtm ð3Þ
where w was a waning parameter that we ﬁxed. The formulation meant that waning reduced ti-
tres to strains in the infection history by a factor e−w per year. If w = 0, then we recovered the
model given by Equation 1.
Results
The model captured the observed age distribution of titres for each of the nine test strains.
Fig. 2 shows that when splines were fitted to the data (red line) and the model (blue line), there
was a similar pattern with age. For time periods that were well represented by test strains in the
data, such as 2003–2008, the model captured both the average pattern of titres with age and the
variability in titre levels for strains in that period (Fig. 2G–I). When test strains circulated fur-
ther away in time from neighbouring data points, the estimates did not match the magnitude
of titre in the serological data as closely. For example, the model overestimated titre levels
against A/Victoria/1975 (Fig. 2B), which was two antigenic clusters from neighbouring test
strains. However, even for time periods that are less well represented in the test strains, such as
1968–1989, the model captured the correct average trend for titre levels. While both the model
and data generally exhibited more variation in titre levels for more recent strains (S1 Fig.),
across all strains, 87% of model estimates were within two dilutions of the observed titre (S2
Fig.).
We found evidence that antigenic seniority and quickly decaying cross-reactivity were im-
portant components of the immune response, and obtained measurements for the immunolog-
ical processes outlined in Fig. 1. Parameter estimates are shown in Table 1. The boosting
parameter suggests that primary infection resulted in a log neutralisation titre of around 3 (cor-
responding to a dilution of 1:40). Our estimate for the exponential decay in cross-reactivity
with time was 0.29, suggesting that strains circulating 2.4 y apart had only 50% cross-reactivity.
The antigenic seniority parameter controlling suppression of subsequent responses was 0.06,
which implies that the response to each new infection was scaled by a factor 0.94 compared
with the response to the previous infecting strain. In contrast, we estimated the parameter that
controlled boosting of prior responses to be zero.
To further investigate our finding that boosting from antigenic seniority was not required in
the model, we compared the observed titre against the earliest strain in each individual’s infec-
tion history with their estimated total number of infections. If in reality subsequent infections
boost earlier responses, we would expect the titre against the earliest strain to be larger for indi-
viduals who have been infected with numerous strains. However, we did not find a significant
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correlation between the two variables, suggesting that boosting from later infections had little
effect on observed neutralisation titres to the first strain (S3 Fig.).
As there may be a trade-off between the short-term and long-term dynamics of influenza in-
fection, we also examined how our estimate for boosting from antigenic seniority changed if
we assumed that titres could wane over time after the initial infection [35–38]. First we tested
Fig 2. Estimated titres by strain and participant age. Black points show observed titre against that strain for each participant. Grey points showmodel
estimates. Red line is spline fitted to the data; blue line shows spline fitted to the model estimates, with the 95% confidence interval given by the shaded
region. (A–I) Results for each of the nine test strains. Parameters in the model are taken from the maximum a posteriori probability estimates. HK, Hong
Kong; ST, Shantou.
doi:10.1371/journal.pbio.1002082.g002
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whether the boosting parameter τ1 could be robustly measured if we included waning in the
model. We found that there was a trade-off between the two processes in the model: a high de-
gree of boosting was balanced by a larger amount of waning. This suggested that these two
mechanisms were not distinguishable given our cross-sectional data (S4 Fig.). We therefore
fixed the degree of waning, and estimated the other parameters. Our estimates for cross-reac-
tivity and measurement error remained consistent. We still found evidence for suppression of
response via antigenic seniority, and if we assumed an increased amount of waning per year,
we obtained a non-zero estimate for antigenic seniority boosting (S1 Table).
In addition, we examined whether broadly cross-reactive antibodies might contribute to ob-
served titres, as has previously been observed during influenza infection [12,39,40]. We extend-
ed the original model described in Equations 1 and 2 to incorporate a fixed amount of broad
cross-reaction between distant strains (S5 Fig.; details in S1 Text). However, when we fitted
this model to data, the parameter estimate for broad cross-reactivity was zero (S2 Table). We
therefore recovered the original model formulation and parameter estimates, which suggested
that broad cross-reactivity was not required to reproduce the observed data.
We were able to better understand how the model reproduced observed titre values for indi-
vidual people by considering specific examples. If a participant was infected with a small num-
ber of strains in the model, observed titres were predominantly the result of boosting (Fig. 3A).
The sharp decay in cross-reactivity in the model meant that a low titre was produced against
strains that circulated a number of years before or after the infecting strain. When participants
were infected with several similar strains, the expected titre was the sum of contributions from
boosting with the test strain and cross-reactivity from related ones (Fig. 3B). Cross-reactivity
also led to a high titre against nearby strains, even if the strains were not in the infection histo-
ry. However, antigenic seniority meant that the contribution to boosting from infection de-
clined with each strain encountered (S6 Fig.). As a result, much of the expected titre against the
first strain came from boosting with that strain, whereas titres to later strains have a larger con-
tribution from cross-reactivity (Fig. 3C). Model residuals for these three selected examples
were representative of the study population (S7 Fig.).
Because we inferred infection histories for each individual, it was also possible to generate
estimates for frequency of infection. Fig. 4A shows the number of A(H3N2) influenza infec-
tions per decade at risk, based on the estimated infection histories. The rate of infection de-
cayed initially with age, but was relatively flat after age 30 y, implying that above a certain age,
individuals were infected with similar frequency. Fig. 4B shows the distribution of time be-
tween two sequential infections, conditional on individuals’ having had at least two infections.
We also tested the ability of the model to predict unseen data. We omitted each of the nine
test strains in turn, refitted the model to the remaining eight strains, and used our parameter
estimates to predict the omitted data. S8 Fig. shows that although the model captured the gen-
eral pattern of measured serological response for many strains, the predictive power was high-
est when test strains were close together in time (S8G–I Fig.).
Table 1. Parameter estimates.
Parameter Deﬁnition Estimate (95% CI)
μ Primary boosting 3.02 (2.66–3.42)
ε Measurement error 0.00 (0.00–0.03)
σ Cross-reactivity 0.29 (0.25–0.33)
τ1 Antigenic seniority (boost prior response) 0.00 (0.00–0.01)
τ2 Antigenic seniority (suppress new response) 0.06 (0.02–0.09)
doi:10.1371/journal.pbio.1002082.t001
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Discussion
We have examined how past infections with influenza A(H3N2) strains influence observed
cross-sectional neutralisation titres. We found that “antigenic seniority” and quickly decaying
cross-reactivity were important components of the immune response. The order in which an
individual is infected with influenza strains was therefore important in dictating observed titres
to a particular virus: titres appeared to be the result of a combination of strain-specific boost-
ing, cross-reactivity, and suppression of subsequent responses as a result of antigenic seniority
(Fig. 5).
Fig 3. Characteristic patterns from different immunemechanisms. (A) Model titres for participant aged
64 y. Parameters in the model are taken from the maximum a posteriori probability estimate. Circles give
observed titres; bars give predicted titres and are coloured by the contribution to immunity from each strain
the individual was infected with (infections are indicated by strains in red on the x-axis). Clusters for which
there are test strains are shown in bold. Here, predicted titres are predominantly the result of boosting, with
little contribution from cross-reactivity. (B) Model titres for participant aged 12 y. Predicted titres for later
strains were the sum of contributions from boosting with the test strain and cross-reactivity from related ones.
(C) Model titres for participant aged 36 y. With each strain encountered, antigenic seniority reduced boosting
to subsequent infections: the coloured bars generated by the infecting strain decrease in size as the number
of infections increases.
doi:10.1371/journal.pbio.1002082.g003
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Our results emphasise the importance of understanding how currently unobserved mecha-
nisms shape the dynamics of influenza for individuals over the course of their lifetime. Tradi-
tionally, analysis of serological data has been descriptive rather than mechanistic. It has
therefore been challenging to distinguish between different hypotheses that could describe ob-
served patterns. In particular, we evaluated two antigenic seniority mechanisms that have been
Fig 4. Frequency of influenza infection. (A) Number of infections per decade at risk. For each participant, this is calculated by dividing the estimated total
number of infections by whichever value is smaller: participant age or 41 (total years between appearance of A(H3N2) in 1968 and test in 2009). Points give
median of the posterior distribution; vertical lines show 95% credible interval. (B) Distribution of time between sequential infections, conditional on having at
least two infections, across all participants and strains.
doi:10.1371/journal.pbio.1002082.g004
Fig 5. Schematic of mechanisms that shape observed titres.Our model suggests that the expected
magnitude of titres that result from a sequence of infections depends on three of the four mechanisms
described in Fig. 1: simple boosting, suppression of subsequent responses as a result of antigenic seniority,
and cross-reaction. The contribution from infecting strains to observed titres is influenced by simple boosting
and suppression via antigenic seniority (A). These contributions, as well as cross-reaction between similar
strains, influence final observed titres (B). For illustrative purposes, strains here appear in 3-y-long epochs,
and have circulated over a 40-y period. Strains the host has been infected with are shown in red; coloured
bars show the magnitude of observed log titre as a result of past infection with each strain.
doi:10.1371/journal.pbio.1002082.g005
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proposed as explanations for why individuals exhibit raised titres to strains encountered earlier
in life [15]: earlier responses could be boosted by subsequent infections, or subsequent re-
sponses could be reduced as a result of prior immunity.
There is an apparent discrepancy between our main parameter estimates for antigenic se-
niority and empirical observations of boosting of antibodies to early infections. Our baseline
results (in the absence of waning) suggest that while there is a reduction in the magnitude of re-
sponse to later infections, the boosting component of antigenic seniority has a negligible effect
on observed long-term titres. However, several studies have found evidence for boosting of ex-
isting responses following influenza infection [13,14,19–21].
There were two mechanisms in our model that could potentially lead to increased titres to
previously encountered strains after subsequent infections. The first was cross-reaction: in our
framework, individuals who had been infected with few strains (Fig. 3A) had lower titres than
those who had been infected with several strains that are antigenically related (Fig. 3C). We as-
sumed cross-reaction was symmetric in the model, and made the same contribution to titres re-
gardless of infection order.
In contrast, we did not find evidence for boosting of earlier responses as a result of antigenic
seniority. In order to investigate this further, we considered the possibility of waning antibodies
as a sensitivity analysis. Unfortunately, with cross-sectional data, the boosting and waning pro-
cesses were not identifiable. Therefore, we assumed a plausible single overall rate of antibody
waning and found evidence for boosting as part of an antigenic seniority process. However, al-
though it was possible to force boosting into the model, we suggest that the identifiability issues
between boosting and waning and the discrepancy between the model parameters and ob-
served boosting are both consequences of the different timescales on which these immunologi-
cal processes occur.
Boosting and waning are both likely to contribute to the hierarchal nature of antibody re-
sponses to influenza. But while waning of elevated titres has been observed over periods of less
than a year [35–38], it is not clear precisely how boosted antibody responses persist over time
in the absence of infection [41]. Based on our model results, we suggest that repeated boosting
of long-lived antibody responses in the absence of waning is unlikely: such a process would
lead to either extremely high titres in older individuals or very low rates of infection, neither of
which seem credible. Therefore, in essence, we believe our model provides a plausible descrip-
tion of the acquisition of a stable set of persistent antibodies.
The apparent discrepancies between observed boosting and relatively low titres to historical
strains further highlight the need for studies that take repeated measurements of the serological
response of individuals against a panel of historical influenza strains [42]. With such data, the
mechanistic model presented here could be expanded to explore both the short- and long-term
dynamics of influenza immunity. This would help elucidate the precise role of boosting and
suppression in antigenic seniority.
We found that cross-reactivity decayed quickly with time, with a half-life of 2.4 y. Hence,
there was little cross-reaction between influenza A(H3N2) strains that circulated several years
apart. We also considered a model that included broad cross-reactivity between strains, but
when we fitted this model to data, the parameter estimate for broad cross-reactivity was zero,
indicating that this additional component was not necessary to reproduce observed serological
patterns. However, there is evidence that individuals are capable of producing broadly cross-re-
active antibodies following infection with a pandemic strain [12,40], and that individuals can
exhibit a longitudinal increase in neutralising titres against pandemic strains that are no longer
circulating [13]. Again, this highlights the need for longitudinal studies of serological responses
against a panel of historical influenza strains. Such data would make it possible to jointly exam-
ine the contribution of broad and strain-specific immune responses, and understand how
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cross-reactive antibodies and antigenic seniority influence observed serological patterns over
multiple timescales.
As well as comparing the effects of different immune mechanisms, we estimated infection
histories for each individual in our study population. We used this information to measure
how frequency of infection varied with age. Although infections became less frequent as indi-
viduals progressed through childhood and young adulthood, they occurred at similar rates for
individuals above age 30 y (Fig. 4A). It has been suggested that influenza transmission is driven
by intense social contacts among younger age groups [43]. The decline in frequency of infec-
tion with age may be the result of age-specific differences in social behaviour. A study con-
ducted in the same area of southern China as our serological survey found intense mixing
within the under-20-y age groups, which could mean the force of infection was higher within
these groups [44]. Unfortunately, we had limited serological data for very young individuals
(the youngest participant in the study was aged 7 y); it would be interesting to see how the fre-
quency of infection changes from birth through childhood.
There are some additional limitations to the work described here. We made no prior as-
sumptions about different age groups’ rate of infection, and hence infection history, in the
model. An important next step would be to develop an approach that could measure force of
infection from cross-sectional data [45]. This could be explored using a model that accounted
for population transmission dynamics as well as serological responses. Moreover, we examined
serological data from only 151 participants in southern China. It would therefore be helpful to
test similar models of serodynamics against observed titres in other populations [42]. We also
focused on responses against a panel of A(H3N2) influenza strains. Unlike group 1 influenza
viruses such as A(H1N1), A(H1N1p), and A(H2N2), no group 2 viruses other than A(H3N2)
have caused a pandemic; it has been suggested that this is why antibody titres specific to HA
stalks might be lower for group 2 viruses than for the more antigenically diverse set of group
1 viruses that have circulated in humans [13]. We also do not distinguish between live infection
and vaccination in the model; different routes of exposure could influence the process of anti-
genic sin/seniority in different ways [12,24].
The model we present offers a novel method for simultaneously investigating immune re-
sponses and past infections. Studies looking at the antigenic relationship between different in-
fluenza strains typically examine cross-reactivity using ferret sera [9,32]. However, the
transmission dynamics of influenza is mediated not just by antigenic change in the virus, but
also by underlying immunity in the host population. To analyse the evolutionary trajectory of
influenza viruses using human sera, it would be necessary to account for past infections, and
how these shape the immune response. We propose that a model of serodynamics, as outlined
in this paper, would provide the theoretical foundation required to tackle this problem.
Our results also have implications for the analysis of control measures. By considering how
a lifetime of infection shapes cross-sectional sera, we have measured the relative importance of
different immune mechanisms and past infections in measured serological responses to influ-
enza. As well as influencing the evolution of influenza, such mechanisms could have an impact
on the effectiveness of vaccination programmes [7].
We found that the model had limited capacity to accurately predict the magnitude of ob-
served titres to strains that circulated several years before or after the strains to which the
model was fitted (S8 Fig.). This is likely the result of the fast decay in cross-reactivity between
strains over time. However, the model could generally predict age-specific trends in titres to
unencountered strains, even those far from the strain used for fitting. It also reproduced the ob-
served titre levels accurately when fitted strains were close to the test strains in time. This sug-
gests that sufficient representation of past strains, perhaps from every antigenic epoch, would
be needed to reproduce all responses accurately. Further, our results were based on
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neutralisation titres. Similar results are likely to be obtained using HAI, albeit with lower speci-
ficity for lower titre values [15,42]. Also, future studies may be able to take advantage of emerg-
ing immunological technology based on high throughput protein microarrays [46] and
sequence-based measures of B cell diversity [47].
Using a model of cross-sectional serological responses, we have assessed the relative impor-
tance of different immune mechanisms and the timing of influenza infection in shaping ob-
served neutralisation titres across the lifetime of an individual. To our knowledge, these two
key factors have not previously been combined to fit immunological data. As well as character-
ising different aspects of the immune response, we have generated individual-level estimates of
the frequency and age distribution of influenza infection from cross-sectional serological data.
These results demonstrate the value of interpreting immune responses in the context of a life-
time of infection. Integrating the life course of immunity into future analyses of influenza dy-
namics could therefore lead to a better understanding of population susceptibility and the
potential transmissibility of new seasonal strains.
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S1 Data. Dataset and model outputs used to generate figures in main text.
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S1 Fig. Change in standard deviation of residuals of spline fit and individual titres over
time. (A) Results from observed data (red line and black points in Fig. 2). (B) Results from
model (blue line and grey points in Fig. 2).
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S2 Fig. Model residuals. The histogram shows the difference in observed titre across all partic-
ipants and test strains and the model maximum a posteriori probability estimate.
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S3 Fig. Relationship between observed titre against primary infection and total estimated
number of infections. If the response to earlier strains was repeatedly boosted after subsequent
infections, we might expect to see a positive correlation between the number of infections and
titre against the first infecting strain. However, there is little evidence of such a relationship: the
Spearman rank correlation coefficient for the two variables is 0.08 (p = 0.43).
(TIFF)
S4 Fig. Joint posterior estimates for waning, w, and antigenic seniority boosting, τ1. There
is strong evidence of a linear relationship between the two: the Spearman rank correlation coef-
ficient for the two variables is 0.87 (p< 0.01).
(TIFF)
S5 Fig. Model with broad and specific cross-reactivity. Specific cross-reactivity decays with
time, controlled by a parameter σ as in the original model, and strains far apart in time exhibit
a fixed broad cross-reactivity, α. Red line, α = 0.1 and σ = 0.3. Blue line, α = 0 and σ = 0.3;
hence, there is no broad cross-reactivity, and the model is equivalent to the original frame-
work.
(TIFF)
S6 Fig. Schematic of antigenic seniority. (A) Reduced response to subsequent infections
using model estimates for individual in Fig. 3B. Bars show the estimated neutralisation titres
generated by each infecting strain in Fig. 3B (i.e., contributions from cross-reactive strains are
not shown). With each subsequent infection, neutralisation titres are reduced as a result of
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antigenic seniority. (B) Reduced titres for individual infection history shown in Fig. 3C.
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S7 Fig. Sum of absolute model residuals across all strains for each participant. Vertical lines
show accuracy of estimates in Fig. 3 compared to other individuals’ estimated titres.
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S8 Fig. Prediction of out-of-sample data. For each strain, the model is fitted using data for
the other eight strains, then parameter estimates are used to predict titre to the ninth. (A–I) Re-
sults for each of the nine test strains. Black points show observed titre against that strain for
each participant. Grey points show model predictions. Red line is spline fitted to the data; blue
line shows spline fitted to the model predictions, with the 95% confidence interval given by the
shaded region.
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